From GlobeNewswire: 2024-03-27 16:01:00

Erasca announced gaining global registrational clarity for naporafenib, along with key clinical milestones for naporafenib, ERAS-007, and ERAS-801. They are expecting multiple data readouts in 2024 and have a robust balance sheet with $322 million in cash, cash equivalents, and marketable securities as of December 31, 2023. Erasca will host an R&D update conference call and webcast on March 28, 2024.

In 2023, Erasca’s three clinical candidates met important clinical and regulatory milestones. They gained Fast Track Designation for naporafenib in combination with trametinib and ERAS-801. For ERAS-007, preliminary data showed potential in combination with encorafenib and cetuximab for colorectal cancer. Erasca has upcoming milestones for naporafenib in 2024, including the initiation of the SEACRAFT-2 trial for NRAS-mutant melanoma.

Erasca has achieved significant milestones for naporafenib and ERAS-801, including gaining regulatory alignment for the pivotal Phase 3 SEACRAFT-2 trial and identifying the maximum tolerated dose for ERAS-801. An analysis of median overall survival data for naporafenib showed promising results. Erasca was granted Fast Track Designation for naporafenib and entered into clinical trial collaboration agreements with Novartis.

Upcoming milestones for Erasca include data readouts for the SEACRAFT-1 trial in patients with RAS Q61X solid tumors and the SEACRAFT-2 trial for NRASm melanoma. Additionally, data is expected for the HERKULES-3 trial for ERAS-007 in patients with BRAFm CRC and the THUNDERBBOLT-1 trial for ERAS-801 in patients with GBM. Erasca also reported financial results with $322.0 million in cash and reduced R&D expenses for the quarter ended December 31, 2023.



Read more at GlobeNewswire:: Erasca Reports Fourth Quarter 2023 and Full Year 2023